DRMA

Dermata Therapeutics, Inc. Common Stock

$1.23

-0.04 (-2.92%)

Volume:

2.341K ($2.88K)

#638 Volume #1164 Dollar Volume

Market Capitalization:

$4.95M

#1500 Market Cap

Dermata Therapeutics Price Chart

Dermata Therapeutics Volume Chart

Dermata Therapeutics Market Segments

Premarket

-0.01(-0.81%)

Open	$1.24
Close	$1.23
Low	$1.23
Low Change	-0.01 (-0.81%)
High	$1.24
High Change	+0.00 (+0.00%)
Range	$0.01
Volume	2.341K
Dollar Volume	$2.88K

After Hours Yesterday

-0.03(-2.42%)

Open	$1.24
Close	$1.21
Low	$1.21
Low Change	-0.03 (-2.42%)
High	$1.24
High Change	+0.00 (+0.00%)
Range	$0.03
Volume	1.6K
Dollar Volume	$1.94K

Regular Trading Hours Yesterday

+0.06(+4.71%)

Open	$1.21
Close	$1.27
Low	$1.21
Low Change	0.00 (0.00%)
High	$1.28
High Change	+0.07 (+5.79%)
Range	$0.07
Volume	47.045K
Dollar Volume	$59.61K

Premarket Yesterday

+0.02(+1.58%)

Open	$1.16
Close	$1.18
Low	$1.16
Low Change	-0.00 (-0.02%)
High	$1.18
High Change	+0.02 (+1.58%)
Range	$0.02
Volume	1.408K
Dollar Volume	$1.66K

Dermata Therapeutics Moving Averages

5 Day Moving Average (SMA5)	$1.26
10 Day Moving Average (SMA10)	$1.30
20 Day Moving Average (SMA20)	$1.28
50 Day Moving Average (SMA50)	$1.29
100 Day Moving Average (SMA100)	$1.76
200 Day Moving Average (SMA200)	$3.38

Dermata Therapeutics Statistics

Average Volume (30 Days)	1.61M
P/E Ratio (Current)	-.64
EPS (Current)	-$1.88
Dividend Yield	0.00%
Free Cash Flow	—
Cash Ratio	4.59
Current Ratio	4.79
Quick Ratio	4.79
Debt to Equity	0.00
Enterprise Value	-$2.66M
EV to EBITDA	0.34
EV to Sales	—
Price to Book	0.78
Price to Cash Flow	—
Price to Free Cash Flow	—
Price to Sales	—
Return on Assets	-0.96%
Return on Equity	-1.21%

Dermata Therapeutics Stock Splits

There have been 3 stock splits for Dermata Therapeutics (DRMA). The last reverse stock split occured on August 1, 2025 and reduced the outstanding shares at a ratio of 10:1.

Date	Type	Ratio
Aug 1, 2025	Reverse	10:1
May 16, 2024	Reverse	15:1
Mar 14, 2023	Reverse	16:1

Dermata Therapeutics Dividends

There have been no dividends for Dermata Therapeutics (DRMA).